Angiogenesis Inducing Agents

• 

  Subject Areas on Research

  • 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) inhibition of coronary vasculogenesis is mediated, in part, by reduced responsiveness to endogenous angiogenic stimuli, including vascular endothelial growth factor A (VEGF-A). 
  • Acidic stress promotes a glioma stem cell phenotype. 
  • An engineered vascular endothelial growth factor-activating transcription factor induces therapeutic angiogenesis in ApoE knockout mice with hindlimb ischemia. 
  • Angiogenesis and molecular biologic substaging in patients with stage I non-small cell lung cancer. 
  • Angiogenic, neurotrophic, and inflammatory system SNPs moderate the association between birth weight and ADHD symptom severity. 
  • Angiogenin-mediated tRNA cleavage as a novel feature of stored red blood cells. 
  • Basic fibroblast growth factor expression following surgical delay of rat transverse rectus abdominis myocutaneous flaps. 
  • Circulating angiogenic factors and abnormal uterine artery Doppler velocimetry in the second trimester. 
  • Current insights on the biology and clinical aspects of VEGF regulation. 
  • Decreases in corporeal vascular endothelial growth factor expression precede vasoreactivity changes in cholesterol fed rabbits. 
  • Effect of low-fat diets on plasma levels of NF-κB-regulated inflammatory cytokines and angiogenic factors in men with prostate cancer. 
  • Evolving revascularization approaches for myocardial ischemia. 
  • Fenoldopam improves corticomedullary oxygen delivery and attenuates angiogenesis gene expression in acute ischemic renal injury. 
  • Growth factors for therapeutic angiogenesis in peripheral arterial disease. 
  • Identification of sokotrasterol sulfate as a novel proangiogenic steroid. 
  • Improved Angiogenesis in Response to Localized Delivery of Macrophage-Recruiting Molecules. 
  • In mice with type 2 diabetes, a vascular endothelial growth factor (VEGF)-activating transcription factor modulates VEGF signaling and induces therapeutic angiogenesis after hindlimb ischemia. 
  • Inhibition of rat corneal angiogenesis by a nuclease-resistant RNA aptamer specific for angiopoietin-2. 
  • Modulation of circulating angiogenic factors and tumor biology by aerobic training in breast cancer patients receiving neoadjuvant chemotherapy. 
  • Molecular approaches for the treatment of atherosclerosis. 
  • Multi-gene targeted antiangiogenic therapies for experimental corneal neovascularization. 
  • Myocardial tissue elastic properties determined by atomic force microscopy after stromal cell-derived factor 1α angiogenic therapy for acute myocardial infarction in a murine model. 
  • Non-viral DNA delivery from porous hyaluronic acid hydrogels in mice. 
  • Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. 
  • Recombinant human platelet-derived growth factor-BB and beta-tricalcium phosphate (rhPDGF-BB/β-TCP): an alternative to autogenous bone graft. 
  • Responses of vascular endothelial cells to angiogenic signaling are important for tumor cell survival. 
  • Serum inter-alpha-trypsin inhibitor and matrix hyaluronan promote angiogenesis in fibrotic lung injury. 
  • Stimulation of endothelial cell prostacyclin release by retina-derived factors. 
  • The CXC chemokine cCAF stimulates precocious deposition of ECM molecules by wound fibroblasts, accelerating development of granulation tissue. 
• 

  Keywords of People

  • McLendon, Roger Edwin, Professor of Pathology, Pathology